What QuidelOrtho Corporation told the SEC could break it.

QuidelOrtho derives a significant portion of revenue from a few customers and distributors: for fiscal 2025 one customer represented 11% of total revenue (and 11% of the North America segment in both 2025 and 2024), with no single customer >10% of accounts receivable. Its revenue is also concentrated by product — respiratory products were ~15% of total revenue in 2025 (down from 24% in 2023 as COVID-19 revenue fell from $409M to $80M), and those products are seasonal (cold/flu/RSV). Loss of, or reduced ordering by, the top customer or a weak respiratory season would meaningfully affect results. The top customer is unnamed, so this registers as a concentration risk.

“We derive a significant portion of our total revenues from a few customers and distributors. For fiscal year ended 2025, one customer represented 11% of Total revenues.”

QuidelOrtho manufactures across the U.S., Pencoed (Wales, U.K.) and Changsha (China) and sources raw materials and components globally, so the 2025 escalation in U.S. trade policy is a direct cost exposure. It discloses that in April 2025 the U.S. announced tariffs on imports from most countries — including significant tariffs on the U.K., Canada, Mexico and China — and that other countries imposed retaliatory tariffs on U.S. goods, with further tariff actions on the sector under consideration. These tariffs raise the cost of importing components/finished diagnostics across its U.K.- and China-linked supply chain and are already affecting its U.S. suppliers, which it is actively managing. A concrete, multi-country trade-policy exposure on its diagnostics supply chain.

“In April 2025, the U.S. announced tariffs on imports from most countries, including significant tariffs on imports from the U.K., Canada, Mexico and China, leading to increasing trade and political tensions.”

QuidelOrtho's diagnostics manufacturing depends on a small number of contract manufacturers and a large number of single- and sole-source suppliers, making it vulnerable to those suppliers' production-capacity or supply-chain constraints, with reduced control over manufacturing, product availability, delivery schedules and costs. It sources raw materials externally and notes some materials are available from only a single or limited number of sources (it names Grifols as an antigen supplier, captured as an edge). It is actively mitigating — partnering for added capacity/inventory, diversifying the supply base where feasible, building redundancy, and insourcing — but a disruption at a sole-source supplier or contract manufacturer could interrupt production of its instruments, reagents and tests. Most suppliers are unnamed, so this registers as a sole-source/limited-supplier risk.

“our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers makes us vulnerable to possible production capacity or other constraints”